

ShareRoot Ltd

12:50 09 Jan 2019

ShareRoot collaborates to support cancer research with MediaConsent

ShareRoot Ltd (ASX:SRO) has entered a collaboration that will see its MediaConsent platform used in a cancer clinical trial setting.

The collaboration is with Cancer Trials Australia (CTA) and the medical project is being led by The Social Science (TSS).

The MediaConsent Medical project now has three health or medical research related collaborators being St Vincent's Hospital, Melbourne, Neuroscience Trials Australia, and CTA.

The shared goal with the MediaConsent clinical collaboration is to demonstrate how ShareRoot's technology protects patient data and privacy whilst supporting the advancement of clinical research.

READ: ShareRoot Ltd attracts new substantial shareholder who has accumulated a 6.8% stake

Project leader Michelle Gallaher said: "The value of data in medical research is only growing as we find better ways to access and use data."

"I'm really pleased to see MediaConsent applied to accelerating medical research and opening new ways for patients and carers to contribute to research by donating their data."

CTA's CEO Kurt Lackovic said: "We recognise the changing interest and value placed on real world data and real world evidence by both global regulators and the biopharma industry in shaping new treatments and products."

A platform like this could really democratise and transform clinical trials, enabling so many more people to participate in research, particularly from remote and regional areas or migrant populations that find it typically difficult to participate in clinical trials."

MediaConsent able to be beneficial in healthcare sector

By collaborating with ShareRoot, clinical researchers can use MediaConsent to access a variety of consented real world data and evidence, in one platform.

Data that may be able to be integrated into the MediaConsent Medical platform may be derived from a number of sources which the patient would give consent for researchers and clinicians to use.

This includes data from social media and the internet, digital health wearables, private and public health records and statistics.

This puts patients in control of their data and ensures clinical researchers are

Price: A\$0.001

Market Cap: A\$1.57M

1 Year Share Price Graph



July 2018 December 2018 July 2019

Share Information

Code: SRO

Listing: ASX

52 week High Low
A\$0.01 A\$0.00

Sector: Tech

Website: www.shareroot.co

Company Synopsis:

ShareRoot Limited (ASX:SRO) is focussed on user generated content licensing, data protection & social media management.

Author:

Proactive Investors Australia

+61 (0)2 9280 0700

action@proactiveinvestors.com.au

compliant with the growing data privacy legislation and regulations around the world.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek personal advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.